Displaying 1 - 3 of 3
Metabolism, Alcohol & Toxicity
2

Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021

View
Metabolism, Alcohol & Toxicity
2

Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021

View
Cirrhosis & Complications
1

Sobi: When Platelet Count Matters: Prophylaxis Ahead of Procedures in Chronic Liver Disease Patients (CLD) - ILC 2021

View